Clarity expands clinical sites for SARTATE™ neuroblastoma trial
Sydney, Australia 8 June 2021 – Clarity Pharmaceuticals, a clinical stage radiopharmaceutical company focused on the treatment of serious disease, is pleased to announce that its clinical trial of 64/67Cu SARTATE™ for paediatric patients with neuroblastoma has been expanded to include five sites in the U.S. “We are very excited to expand into additional clinical…